2-Methoxyestradiol (2ME2) is a drug that prevents the formation of new blood vessels that tumors need in order to grow (angiogenesis). It has undergone Phase 1 clinical trials against breast... It has undergone Phase 1 clinical trials against breast cancers and preclinical studies suggest that 2ME2 could also be effective against inflammatory diseases such as rheumatoid arthritis.
- Mechanism
- Curator reviewed
2-Methoxyestradiol is an angiogenesis inhibitor, and has been shown to attack both tumor cells and their blood supply in preclinical testing. 2-methoxyestradiol is a naturally occurring estrogen metabolite but has no undesired estrogenic activity.
- Primary indication
- For the treatment of breast cancer and inflammatory diseases such as rheumatoid arthritis.Curator reviewed
- Formula / weight
- C19H26O3 · 302.4079 g/mol (avg)
- Also known as
- 2-ME2 · 2-Methoxyestradiol-17beta · 2ME2
Resolves to
CQOQDQWUFQDJMK-SSTWWWIQSA-NSMILES[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C(OC)=C3What you can answer from here — as of September 23, 2026
Which drugs share a target with 2-Methoxyestradiol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account